Protecting Newborn From Pertussis

Abstract

Whooping cough is an acute, contagious respiratory disease that can be fatal in childhood, with serious complications, especially in newborns and early infancy. Life-long immunity is not achieved with childhood pertussis vaccination. Infants who do not have protective antibodies belong to their mothers are susceptible to pertussis infection until they develop immunity with childhood pertussis vaccination. In this period, strategies have been developed to protect infants from infection with pertussis. In this review, the protection methods of newborn pertussis by “cocoon strategy” and “maternal immunization” were evaluated.

Keywords

• pertussis,newborn,cocoon strategy,maternal immunization

Yenidoğanın Boğmacadan Korunması

Abstract

Boğmaca, çocukluk çağında ciddi komplikasyonlarla seyreden, özellikle yenidoğan ve erken bebeklikte ölümcül olabilen akut, bulaşıcı bir solunum yolu hastalığıdır. Çocukluk çağında yapılan boğmaca aşısı ile ömür boyu bağışıklık sağlanamamaktadır. Anneden geçen koruyucu antikorları olmayan bebekler boğmaca aşısı ile immünite oluşturana kadar boğmaca enfeksiyonuna duyarlıdır. Bu dönemde bebekleri boğmaca enfeksiyonundan korumaya yönelik stratejiler geliştirilmiştir. Bu derlemede yenidoğanı boğmacadan “koza stratejisi” ve “maternal bağışıklama” ile koruma yöntemleri değerlendirilmiştir.

Keywords

• boğmaca,yenidoğan,koza stratejisi,maternal bağışıklama

References

1. Long SS, Pickering LK, Prober CG (Eds). Principles and Practice of Pe- diatric Infectious Disease, 4. Edition, USA, 2012.
2. Pertussis (Whooping Cough). Centers for Disease Control and Preventi- on. Atlanta, GA: CDC/Outbreaks: Access date: 03.07.2017)
3. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining per- tussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005;24(5 Suppl):S25-34.
4. Cortese MM, Baughman AL, Zhang R, Srivastava PU, Wallace GS. Per- tussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics. 2008;121(3):484-92.
5. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26(4):293-9.
6. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004;23(11):985-9.
7. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58-61.
8. Centers for Disease Control and Prevention. Updated recommendati- ons for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged

9. Perret C, Viviani T, Pena A, Abarca K, Ferres M. [Source of infection in young infants hospitalized with Bordetella pertussis]. Rev Med Chil. 2011;139(4):448-54.
10. Centers for Disease Control and Prevention. Epidemiology and Preven- tion of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015.
11. Terranella A, Asay GR, Messonnier ML, Clark TA, Liang JL. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a de- cision analysis. Pediatrics. 2013;131(6):e1748-56.
12. Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. Cost-effec- tiveness analysis of various pertussis vaccination strategies primarily ai- med at protecting infants in the Netherlands. Clin Ther. 2010;32(8):1479- 95.
13. Lugner AK, van der Maas N, van Boven M, Mooi FR, de Melker HE. Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine. 2013;31(46):5392-7.
14. Krishnaswamy S, Wallace EM, Cheng AC, Buttery J, Giles ML. Pro- tecting newborns from pertussis: The role of partner vaccination in the era of maternal immunization. Eur J Obstet Gynecol Reprod Biol. 2017;216:159-63.
15. Kafes FD, Aslan G, Yarpuzlu M, Kuyucu N, Emekdaş G. Adölesan ve genç erişkin bireylerde Bordetella pertussis seroprevalansının belirlenmesi. J Pediatr Inf 2013;7: 136-4
16. Ercan TE, Sonmez C, Vural M, Erginoz E, Torunoglu MA, Perk Y. Serop- revalance of pertussis antibodies in maternal and cord blood of preterm and term infants. Vaccine. 2013;31(38):4172-6.
17. Halasa NB, O’Shea A, Shi JR, LaFleur BJ, Edwards KM. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr. 2008;153(3):327-32.
18. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a rando- mized clinical trial. JAMA. 2014;311(17):1760-9.
19. Abu Raya B, Srugo I, Kessel A, Peterman M, Bader D, Gonen R, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study. Vaccine. 2014;32(44):5787-93.
20. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004;190(2):335-40.
21. ACOG Committee Opinion No. 566: Update on immunization and preg- nancy: tetanus, diphtheria, and pertussis vaccination. Obstet Gynecol. 2013;121(6):1411-4.
22. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged
23. Tdap (Tetanus, Diphtheria, Pertussis) Vaccine Information Statements www.cdc.gov/vaccinesafety/.../vaers/publications.html (available date: 17.08.17).